Sophocarpine
Catalog No: CFN99182
Sophocarpine has anti-cachectic, anti-inflammatory, and neuroprotective effects. It has significant antivirus effects against coxsackievirus B3 and therapeutic effects for viral myocarditis in clinical, can ameliorate the ischemic injury induced by transient focal cerebral ischemia in rats, and may be a potential chemotherapeutic agent for chronic liver diseases. Sophocarpine inhibited the expression of TNF-alpha, IL-6, JNK, iNOS, COX-2, p38 MAPK, NF-κB, TLR4, and activated signaling pathway of AMPK.
Sophocarpine
Catalog No: CFN94852
Sophocarpine has anti-cancer, anti-inflammatory, anti-nociceptive, and antivirus activities, it can prevent implant loosening through inhibiting osteoclast formation and bone resorption, thus, it may be a novel therapeutic agent to prevent prosthesis loosening and for osteolytic diseases. Sophocarpine could attenuate ConA-induced liver injury, and the protective effect of Sophocarpine was associated with its inhibition effect of pro-inflammatory cytokines, chemokines, and the IFN-γ/STAT1 signaling pathway.
Sophoridine
Catalog No: CFN97172
Sophoridine has anti-inflammatory, anti-cancer and anti-arrhythmia, and affects the immune and central nervous systems. Early and short-time applying sophoridine has neuroprotective effect min permanent middle cerebral artery occlusion (pMCAO) rat brain by down-regulating TRAF6 and up-regulating p-ERK1/2 expression, ameliorating brain infaction and edema. Sophoridine also possesses antiviral activities against Coxsackievirus B3, by regulating cytokine expression, may represent a potential therapeutic agent for viral myocarditis.
Sorafenib
Catalog No: CFN90012
Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.Sorafenib together with inhibitors of the β-catenin pathway might be an effective tool in the treatment of pediatric HCC. The combination of Sorafenib with AMPK activators could have beneficial effects on tumor regression by AMPK pathway activation. The combination of metformin or other AMPK activators and Sorafenib could be tested in prospective clinical trials.